5-羟色胺选择性重摄取抑制剂治疗阿尔茨海默病伴发抑郁症患者有效性和安全性的meta分析  

Meta analysis on the efficacy and safety of selective serotonin reuptake inhibitor in the treatment of Alzheimer’s disease with depression

作　　者：宋帆 唐新龙 程凤先 童庆好 SONG Fan;TANG Xinlong;CHENG Fengxian;TONG Qinghao(Department of Psychiatry,Affiliated Hospital of West Anhui Health Vocational College,Anhui Province,Luan 237010,China)

机构地区：[1]皖西卫生职业学院附属医院精神科,安徽六安237010

出　　处：《中国医药导报》2022年第20期75-78,共4页China Medical Herald

基　　金：皖西卫生职业学院省级一般科研项目(KJ2020B 006)。

摘　　要：目的系统评价5-羟色胺选择性重摄取抑制剂(SSRIS)治疗阿尔茨海默病(AD)伴发抑郁症患者的有效性和安全性。方法计算机检索PubMed、Embase、中国知网、万方数据库、维普网,检索时限均从建库至2021年5月。由2名研究者独立筛选文献、提取资料并评价文献的偏倚风险,采用RevMan 5.3软件进行meta分析。结果共纳入7篇研究,438例患者。meta分析结果显示:两组有效率(OR=2.33,95%CI:0.69~7.91,P=0.17)、康耐尔痴呆抑郁量表评分(MD=-2.52,95%CI:-6.19~1.15,P=0.18)、简易精神状态检查量表评分(MD=-0.30,95%CI:-0.82~1.41,P=0.60)、不良反应发生率(OR=1.21,95%CI:0.65~2.26,P=0.55)比较,差异均无统计学意义。结论SSRIS治疗AD伴发抑郁症患者的有效性和安全性与安慰剂相当。Objective To systematically evaluate the efficacy and safety of serotonin-selective reuptake inhibitor(SSRIS)in the treatment of Alzheimer’s disease patients with depression.Methods The databases of PubMed,Embase,CNKI,Wanfang Data,VIP were electronically searched for relevant studies from inceptions to May 2021.Two reviewers independently screened the literature,extracted data and assessed the methodolgical quality.And meta analysis was performed by using RevMan 5.3.Results A total of seven studies with 438 patients were included.The results of meta analysis showed that there were no significant differences in the effective rate(OR=2.33,95%CI:0.69-7.91,P=0.17),the score of Cornell scale for depression in dementia(MD=-2.52,95%CI:-6.19-1.15,P=0.18),the score of simple mental state examination scale(MD=-0.30,95%CI:-0.82-1.41,P=0.60)and the incidence of adverse reactions(OR=1.21,95%CI:0.65-2.26,P=0.55)between two groups.Conclusion The efficacy and safety of SSRIS in the treatment of patients with AD concomitant depression are comparable to that of placebo.

关 键 词：选择性5-羟色胺再摄取抑制剂 阿尔茨海默病 抑郁症 有效性 安全性 META分析 

分 类 号：R742.8[医药卫生—神经病学与精神病学]